Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...

In a report released yesterday, David Risinger from Leerink Partners reiterated a Buy rating on Roivant Sciences (ROIV – Research ...

Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...

Analysts at Leerink Partnrs lifted their FY2025 EPS estimates for shares of Opthea in a report released on Tuesday, October ...

Research analysts at Leerink Partnrs cut their Q3 2024 earnings per share (EPS) estimates for Biohaven in a report released ...

Leerink Partners has maintained its Market Perform rating and $4.00 price target for Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX). The firm acknowledged the encouraging new HELIOS open-label data ...

On Friday, Accolade Inc (ACCD) stock saw a decline, ending the day at $3.5 which represents a decrease of $-0.08 or -2.23% from the prior close of $3.58. The stock opened at $3.59 and touched a low of ...

Leerink Partners analysts are forecasting annual sales of $866 million in 2026, compared to a consensus of $362 million. The ...

Prospects for a potential merger between health insurers Cigna Group and Humana Inc. hinge on the upcoming US presidential election, analysts said.

Leerink assumed coverage of Mind Medicine with an Outperform rating and $20 price target The firm likes the emerging ...